IGF-1, IGFBP-1, and IGFBP-3 Polymorphisms Predict Circulating IGF Levels but Not Breast Cancer Risk: Findings from the Breast and Prostate Cancer Cohort Consortium (BPC3)

• Alpa V. Patel ,

  * E-mail: apatel@cancer.org

  Affiliation Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, Georgia, United States of America

  ⨯
• Iona Cheng,

  Affiliation Department of Epidemiology and Biostatistics, Institute for Human Genetics, University of California San Francisco, San Francisco, California, United States of America

  ⨯
• Federico Canzian,

  Affiliation Genomic Epidemiology Group, German Cancer Research Center, Heidelberg, Germany

  ⨯
• Loïc Le Marchand,

  Affiliation Epidemiology Program, Cancer Research Center, University of Hawaii, Honolulu, Hawaii, United States of America

  ⨯
• Michael J. Thun,

  Affiliation Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, Georgia, United States of America

  ⨯
• Christine D. Berg,

  Affiliation Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, United States of America

  ⨯
• Julie Buring,

  Affiliation Division of Preventive Medicine, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Eugenia E. Calle,

  Affiliation Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, Georgia, United States of America

  ⨯
• Stephen Chanock,

  Affiliation Core Genotyping Facility, National Cancer Institute, Gaithersburg, Maryland, United States of America

  ⨯
• Francoise Clavel-Chapelon,

  Affiliation INSERM, Institut Gustave Roussy, Villejuif, France

  ⨯
• David G. Cox,

  Affiliation Program in Molecular and Genetic Epidemiology, Epidemiology Department, Harvard School of Public Health, Boston, Massachusetts, United States of America

  ⨯
• Miren Dorronsoro,

  Affiliation Department of Public Health of Guipuzcoa, San Sebastian, Spain

  ⨯
• Laure Dossus,

  Affiliation Division of Cancer Epidemiology, German Cancer Research Centre (DKFZ), Heidelberg, Germany

  ⨯
• Christopher A. Haiman,

  Affiliation University of Southern California, Los Angeles, California, United States of America

  ⨯
• Susan E. Hankinson,

  Affiliation Department of Medicine, Channing Laboratory, Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Brian E. Henderson,

  Affiliation University of Southern California, Los Angeles, California, United States of America

  ⨯
• Robert Hoover,

  Affiliation Core Genotyping Facility, National Cancer Institute, Gaithersburg, Maryland, United States of America

  ⨯
• David J. Hunter,

  Affiliation Program in Molecular and Genetic Epidemiology, Epidemiology Department, Harvard School of Public Health, Boston, Massachusetts, United States of America

  ⨯
• Rudolf Kaaks,

  Affiliation Division of Cancer Epidemiology, German Cancer Research Centre (DKFZ), Heidelberg, Germany

  ⨯
• Laurence N. Kolonel,

  Affiliation Epidemiology Program, Cancer Research Center, University of Hawaii, Honolulu, Hawaii, United States of America

  ⨯
• Peter Kraft,

  Affiliation Program in Molecular and Genetic Epidemiology, Epidemiology Department, Harvard School of Public Health, Boston, Massachusetts, United States of America

  ⨯
• Jakob Linseisen,

  Affiliation Division of Cancer Epidemiology, German Cancer Research Centre (DKFZ), Heidelberg, Germany

  ⨯
• Eiliv Lund,

  Affiliation Institute of Community Medicine, University of Tromsö, Tromsö, Norway

  ⨯
• Jonas Manjer,

  Affiliation Department of Surgery, Malmö University Hospital, Malmö, Sweden

  ⨯
• Catherine McCarty,

  Affiliation The Center for Human Genetics, Marshfield Clinic Research Foundation, Marshfield, Wisconsin, United States of America

  ⨯
• Petra H. M. Peeters,

  Affiliations Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands, Department of Epidemiology and Public Health, Imperial College, London, United Kingdom

  ⨯
• Malcolm C. Pike,

  Affiliation University of Southern California, Los Angeles, California, United States of America

  ⨯
• Michael Pollak,

  Affiliation Department of Oncology, McGill University, Montreal, Quebec, Canada

  ⨯
• Elio Riboli,

  Affiliation Department of Epidemiology and Public Health, Imperial College, London, United Kingdom

  ⨯
• Daniel O. Stram,

  Affiliation University of Southern California, Los Angeles, California, United States of America

  ⨯
• Anne Tjonneland,

  Affiliation Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark

  ⨯
• Ruth C. Travis,

  Affiliation Cancer Research UK Epidemiology Unit, University of Oxford, Oxford, United Kingdom

  ⨯
• Dimitrios Trichopoulos,

  Affiliation Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, United States of America

  ⨯
• Rosario Tumino,

  Affiliation Cancer Registry Azienda Ospedaliera “Civile M.P. Arezzo”, Ragusa, Italy

  ⨯
• Meredith Yeager,

  Affiliation Core Genotyping Facility, National Cancer Institute, Gaithersburg, Maryland, United States of America

  ⨯
• Regina G. Ziegler,

  Affiliation Division of Cancer Epidemiology and Genetics, National Cancer Institute (NCI), US National Institutes of Health (NIH), Department of Health and Human Services (DHHS), Bethesda, Maryland, United States of America

  ⨯
•  [ ... ],
• Heather Spencer Feigelson

  Affiliation Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, Georgia, United States of America

  ⨯
• [ view all ]
• [ view less ]